Sun Pharma comes out of red in Q1

MUMBAI: Sun Pharma reported a consolidated net profit of Rs 1,444 crore for the quarter ended June as against a net loss of Rs 1,655 crore in the year-ago quarter, buoyed by robust sales in major markets including India and the US. Consolidated sales from operations stood at Rs 9,669 crore, a growth of 29% over Q1 in the previous year and 14% over preceding Q4, a company statement said.
Sales of branded formulations in India for Q1FY22 were at Rs 3,308 crore, up by 39%, and accounting for 34% of total sales. While US sales were $380 million, a growth of 35% over year-ago and 3% sequentially, accounting for about 29% of total sales. Sun Pharma MD Dilip Shanghvi said, “We witnessed a strong Q1.”